GUTS · XBRL financial data

Fractyl Health financial statements, every quarter

The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (GUTS's year ends in late December)

In thousands of dollars	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cost of revenue	19	24	7	0*	—	—	—	year only	—	—
Gross profit	14	19	7	—	—	—	—	—	—	—
Research and development	14,424	16,762	19,004	20,281*	19,435	21,151	17,457	16,493*	15,598	13,812
Selling, general and administrative	7,132	6,242	4,797	4,932*	5,324	4,928	5,237	6,791*	5,222	5,284
Total operating expenses	21,556	23,004	23,801	25,213*	24,759	26,079	22,694	23,284*	20,820	19,096
Operating income (loss)	(21,542)	(22,985)	(23,794)	(25,210)*	(24,759)	(26,079)	(22,694)	(23,284)*	(20,820)	(19,096)
Interest income	1,098	1,375	947	726*	503	226	166	645*	593	431
Other income (expense)	(10)	(18)	(9)	(10)*	(21)	(15)	(6)	(11)*	—	(7)
Income tax expense (benefit)	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(3,322)	(17,229)	(23,173)	(24,970)*	(23,735)	(27,889)	(45,603)	(43,727)*	9,218	(25,538)
Earnings per share, basic USD per share	(0.17)	(0.36)	(0.48)	—	(0.49)	(0.57)	(0.71)	—	0.06	(0.16)
Earnings per share, diluted USD per share	(0.17)	(0.36)	(0.48)	—	(0.49)	(0.57)	(0.71)	—	0.06	(0.16)
Weighted average shares, basic thousands of shares	29,737	47,899	47,974	48,453*	48,865	49,043	64,653	—	158,492	158,649
Weighted average shares, diluted thousands of shares	29,737	47,899	47,974	48,453*	48,865	49,043	64,653	—	158,492	158,649

Fiscal quarters (GUTS's year ends in late December)

In thousands of dollars	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	121,441	102,439	84,664	67,464	42,108	22,291	77,657	81,540	63,168	47,140
Accounts receivable	15	22	0	0	—	—	—	—	—	—
Inventory	73	64	73	73	—	—	—	—	—	—
Prepaid and other current assets	—	—	—	—	—	—	—	6,036	—	2,462
Total current assets	124,472	106,555	87,651	71,763	47,045	26,688	79,703	87,576	65,920	49,602
Property and equipment, net	1,902	3,172	3,000	2,979	3,137	2,965	2,683	2,407	2,126	1,848
Right-of-use asset	29,613	29,151	28,787	28,414	28,032	27,640	27,239	26,827	26,403	25,967
Total assets	163,519	146,437	126,924	108,077	83,040	62,006	114,272	121,402	99,385	81,976
Accounts payable	1,027	2,287	1,767	3,240	1,479	3,911	1,261	1,574	1,649	1,006
Total current liabilities	13,272	14,281	15,717	19,775	18,801	21,832	18,682	18,329	15,408	15,736
Lease liability, non-current	28,246	27,974	27,694	27,382	27,048	26,704	26,347	25,956	25,540	25,110
Total liabilities	79,341	75,682	76,602	79,653	76,665	80,218	117,450	111,944	78,008	83,641
Accumulated deficit	(349,938)	(367,167)	(390,340)	(415,310)	(439,045)	(466,934)	(512,537)	(556,264)	(547,046)	(572,584)
Total stockholders' equity	84,178	70,755	50,322	28,424	6,375	(18,212)	(3,178)	9,458	21,377	(1,665)
Total liabilities and equity	163,519	146,437	126,924	108,077	83,040	62,006	114,272	121,402	99,385	81,976
Common shares outstanding (cover page) thousands of shares	47,897	47,927	48,099	48,920	48,977	50,289	137,044	158,649	158,649	159,180

Fiscal quarters (GUTS's year ends in late December)

In thousands of dollars	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(3,322)	(17,229)	(23,173)	(24,970)*	(23,735)	(27,889)	(45,603)	(43,727)*	9,218	(25,538)
Stock-based compensation	5,217	3,790*	2,520*	2,899*	1,406	1,785*	1,638*	1,855*	2,531	2,496*
Net cash from operating activities	(11,711)	(18,737)*	(18,039)*	(17,034)*	(25,079)	(21,199)*	(22,714)*	(21,336)*	(22,477)	(15,901)*
Purchases of property and equipment	1,059	260*	213*	233*	448	98*	8*	3*	—	—
Net cash from investing activities	(1,059)	(260)*	(213)*	(233)*	(448)	(98)*	(8)*	(3)*	—	—
Proceeds from issuing common stock	—	—	—	—	—	—	477*	4,709*	170	—
Net cash from financing activities	101,002	(5)*	162*	67*	171	1,480*	78,088*	25,222*	4,105	(127)*
Net change in cash	88,232	(19,002)*	(18,090)*	(17,200)*	(25,356)	(19,817)*	55,366*	3,883*	(18,372)	(16,028)*

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Fractyl Health	47,140	not reported	(15,901)*	159.2M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Vivos	2,336	36	(740)*	494.2M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Vivani Medical	19,894	not reported	(6,035)*	90.2M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Xtant Medical Holdings	9,870	23,031	(7,308)*	140.3M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Hyperfine	43,458	3,904	(7,268)*	not reported	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Monogram Technologies	12,834	not reported	(2,297)*	40.6M	5.6 quarters	Q2 FY25 10-QJun 30, 2025
Alpha Pro Tech	18,901	not reported	2,213*	10.2M	—	Q2 FY26 10-QJun 30, 2026
Nuo Therapeutics	449	not reported	(236)*	48.4M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Cytosorbents	4,413	9,633	(583)*	62.8M	7.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.